Abstract:Abstract Frequent inactivation of transforming growth factor β (TGFβ) pathway core components in pancreatic ductal adenocarcinoma (PDA), especially the transcription factor SMAD4, suggests that TGFβ signaling is tumor suppressive in the pancreas. Yet, 50% of PDA retains an intact core TGFβ pathway, suggesting that there are mechanisms by which these tumors escape TGFβ-mediated tumor suppression. In unpublished work, we have delineated a mechanism for TGFβ-mediated tumor suppression via a lethal epithelial-mesenchymal transition (EMT). Based on clinical and in vitro evidence that AKT activation may suppress the lethal EMT response to TGFβ, we are investigating the role of AKT signaling in directly interfering with TGFβ-mediated tumor suppression. We have taken two major approaches: (1) to test the concept that AKT inhibition may reactivate TGFβ-mediated tumor suppression, we are chemically inhibiting AKT in PDA mouse models competent and deficient in TGFβ signaling, and (2) to understand the mechanism of AKT-TGFβ crosstalk in PDA progression, we are performing RNAseq-based gene expression profiling of SMAD4-restored PDA cell lines. We have found that in vitro, AKT signaling determines whether TGFβ induces apoptosis in SMAD4-restored PDA cell lines, and by gene expression analysis, we have identified a group of genes that are differentially regulated by TGFβ in the presence and absence of AKT signaling. Furthermore, we have characterized FOXO immunohistochemical staining as a reliable marker for AKT inhibition status and developed an in vivo system in which we are testing whether AKT inhibition may be a means to reactivate TGFβ-mediated tumor suppression in PDA. Our studies indicate that AKT signaling may alter the outcome of TGFβ-mediated tumor suppression in the pancreas, and our ongoing work is aimed at dissecting the AKT-modulated transcriptional mechanisms that determine the outcome of TGFβ signaling and the consequences of this crosstalk in tumor progression. Citation Format: Yun-Han Huang, Charles David, Joan Massague. AKT activation as a mechanism of escape from TGFβ-mediated lethal EMT. [abstract]. In: Proceedings of the AACR Special Conference: Developmental Biology and Cancer; Nov 30-Dec 3, 2015; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(4_Suppl):Abstract nr A30.

ID1 Mediates Escape from TGF-β Tumor Suppression in Pancreatic Cancer.

Figure S1 from ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer

Abstract A30: AKT Activation As a Mechanism of Escape from TGFβ-mediated Lethal EMT

ID1 marks the tumorigenesis of pancreatic ductal adenocarcinoma in mouse and human

Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.

Figure S6 from ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer

Figure S2 from ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer

TGF-β Tumor Suppression Through a Lethal EMT

PDX1 Dynamically Regulates Pancreatic Ductal Adenocarcinoma Initiation and Maintenance.

DDX18 drives tumor immune escape through transcription-activated STAT1 expression in pancreatic cancer

Targeting TGFβR2‐mutant Tumors Exposes Vulnerabilities to Stromal TGFβ Blockade in Pancreatic Cancer

Loss of the Transcriptional Repressor TGIF1 Results in Enhanced Kras-driven Development of Pancreatic Cancer

TBL1XR1 Induces Cell Proliferation and Inhibit Cell Apoptosis by the PI3K/AKT Pathway in Pancreatic Ductal Adenocarcinoma.

Cell-intrinsic PD-1 Promotes Proliferation in Pancreatic Cancer by Targeting CYR61/CTGF Via the Hippo Pathway

IGFBP2 Drives Regulatory T Cell Differentiation through STAT3/IDO Signaling Pathway in Pancreatic Cancer

Protein kinase D1 drives pancreatic acinar cell reprogramming and progression to intraepithelial neoplasia

IDO-1 inhibitor INCB24360 elicits distant metastasis of basal extruded cancer cells in pancreatic ductal adenocarcinoma

IGFBP2 Drives Regulatory T Cell Differentiation through STAT3/IDO Signaling Pathway in Pancreatic Cancer.

PDCD10 promotes the tumour-supporting functions of TGF-β in pancreatic cancer

Loss of p53 tumor suppression function drives invasion and genomic instability in models of murine pancreatic cancer

Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer